NCT05585151View on ClinicalTrials.gov

High-Resolution Assessment of Extracranial Plaques in a Multiple Centers Evolocumab Randomized Study

PHASE4RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

November 9, 2022

Primary Completion Date

April 1, 2024

Study Completion Date

October 1, 2024

Conditions
Cerebral Atherosclerosis
Interventions
DRUG

Evolocumab 140 MG/ML

Evolocumab 140mg, subcutaneous injection, every 2 weeks, for 26 week, total 13 times

DRUG

Intensive statin treatment

Intensive statin could choose either Atorvastatin 40mg/day or Rosuvastatin 20mg/day, for 26 weeks

Trial Locations (1)

430022

RECRUITING

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER